A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia Journal Article
| Authors: | Wingard, J. R.; White, M. H.; Anaissie, E.; Raffalli, J.; Goodman, J.; Arrieta, A. |
| Article Title: | A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia |
| Abstract: | In this double-blind study to compare safety of 2 lipid formulations of amphotericin B, neutropenic patients with unresolved fever after 3 days of antibacterial therapy were randomized (1:1:1) to receive amphotericin B lipid complex (ABLC) at a dose of 5 mg/kg/d (n = 78), liposomal amphotericin B CL Amph) at a dose of 3 mg/kg/d (n = 85), or L Amph at a dose of 5 mg/kg/d (n = 81). L Amph (3 mg/kg/d and 5 mg/kg/d) had lower rates of fever (23.5% and 19.8% vs. 57.7% on day 1; P<.001), chills/rigors (18.8% and 23.5% vs. 79.5% on day 1; P<.001), nephrotoxicity (14.1% and 14.8% vs. 42.3%; P<.01), and toxicity-related discontinuations of therapy (12.9% and 12.3% vs. 32.1%; P =.004). After day 1, infusional reactions were less frequent with ABLC, but chills/rigors were still higher (21.0% and 24.3% vs. 50.7%; P<.001). Therapeutic success was similar in all 3 groups. |
| Keywords: | fever; therapy; antifungal; aspergillosis; prevention; formulations; invasive fungal-infections; deoxycholate |
| Journal Title: | Clinical Infectious Diseases |
| Volume: | 31 |
| Issue: | 5 |
| ISSN: | 1058-4838 |
| Publisher: | Oxford University Press |
| Date Published: | 2000-11-15 |
| Start Page: | 1155 |
| End Page: | 1163 |
| Language: | English |
| ACCESSION: | WOS:000165704400010 |
| DOI: | 10.1086/317451 |
| PROVIDER: | wos |
| PUBMED: | 11073745 |
| Notes: | Article -- Source: Wos |
